Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/11142
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | DEJARDIN, David | - |
dc.contributor.author | LESAFFRE, Emmanuel | - |
dc.contributor.author | VERBEKE, Geert | - |
dc.date.accessioned | 2010-09-07T07:48:56Z | - |
dc.date.available | NO_RESTRICTION | - |
dc.date.available | 2010-09-07T07:48:56Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | STATISTICS IN MEDICINE, 29 (16). p. 1724-1734 | - |
dc.identifier.issn | 0277-6715 | - |
dc.identifier.uri | http://hdl.handle.net/1942/11142 | - |
dc.description.abstract | Progression-related endpoints (such as time to progression or progression-free survival) and time to death are common endpoints in cancer clinical trials. It is of interest to study the link between progression-related endpoints and time to death (e.g. to evaluate the degree of surrogacy). However, current methods ignore some aspects of the definitions of progression-related endpoints. We review those definitions and investigate their impact on modeling the joint distribution. Further, we propose a multi-state model in which the association between the endpoints is modeled through a frailty term. We also argue that interval-censoring needs to be taken into account to more closely match the latent disease evolution. The joint distribution and an expression for Kendall's tau are derived. The model is applied to data from a clinical trial in advanced metastatic ovarian cancer. Copyright (C) 2010 John Wiley & Sons, Ltd. | - |
dc.language.iso | en | - |
dc.publisher | JOHN WILEY & SONS LTD | - |
dc.subject.other | survival; time to progression; frailty models; progressive multi-state models; interval censoring | - |
dc.subject.other | survival; time to progression; frailty models; progressive multi-state models; interval censoring | - |
dc.title | Joint modeling of progression-free survival and death in advanced cancer clinical trials | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1734 | - |
dc.identifier.issue | 16 | - |
dc.identifier.spage | 1724 | - |
dc.identifier.volume | 29 | - |
local.format.pages | 11 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Dejardin, David; Lesaffre, Emmanuel; Verbeke, Geert] Katholieke Univ Leuven, Interuniv Inst Biostat & Stat Bioinformat, B-3000 Louvain, Belgium. [Dejardin, David; Lesaffre, Emmanuel; Verbeke, Geert] Univ Hasselt, B-3000 Louvain, Belgium. [Dejardin, David] Bristol Myers Squibb Co, Global Biometr Sci, B-1420 Braine Ialleud, Belgium. [Lesaffre, Emmanuel] Erasmus MC, Dept Biostat, Rotterdam, Netherlands. david.dejardin@med.kuleuven.be | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.doi | 10.1002/sim.3918 | - |
dc.identifier.isi | 000279858000006 | - |
item.contributor | DEJARDIN, David | - |
item.contributor | LESAFFRE, Emmanuel | - |
item.contributor | VERBEKE, Geert | - |
item.validation | ecoom 2011 | - |
item.fulltext | With Fulltext | - |
item.accessRights | Restricted Access | - |
item.fullcitation | DEJARDIN, David; LESAFFRE, Emmanuel & VERBEKE, Geert (2010) Joint modeling of progression-free survival and death in advanced cancer clinical trials. In: STATISTICS IN MEDICINE, 29 (16). p. 1724-1734. | - |
crisitem.journal.issn | 0277-6715 | - |
crisitem.journal.eissn | 1097-0258 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
dejardin 1.pdf Restricted Access | Published version | 226.01 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
11
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
12
checked on Oct 12, 2024
Page view(s)
210
checked on Sep 7, 2022
Download(s)
200
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.